1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Valuation
Discussion
Symbol
NRXS
Event Date
2023-08-09
Sector
Health Care
Subsector
Health Care Equipment & Supplies
Offer Range
$6.00
Shares Offered
1.1M
6.59M
$39.6M
16.7%
Implied Upside vs Midpoint
Description
We are a medical technology company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. We are dedicated to advancing science with our proprietary IB-Stim therapy, based on our PENFS technology, which we developed. We believe that superior science and evidence-based research are necessary for adoption by the medical and scientific community. With one FDA indicationÑfunctional abdominal pain associated with IBS in adolescents 11-18 years oldÑon the market, additional clinical trials of PENFS in multiple pediatric conditions are underway focused on unmet healthcare needs in children. We expect to incur significant expenses and operating losses for the foreseeable future as we continue to pursue widespread insurance coverage of our IB-Stim device and seek FDA clearance of our device for other indications. There are a number of milestones and conditions that we must satisfy before we will be able to generate sufficient revenue to fund our operations, including FDA clearance of our IB-Stim device to treat future indications. Our mission is to provide solutions that create value and provide better and safer patient outcomes. We believe in improving lives and minimizing suffering, particularly in the pediatric population, where research and therapeutics are usually lacking. The FDA has already cleared our IB-Stim therapy for functional abdominal pain, associated with IBS, in children. Through innovation and research, we are reimagining the future of patient care. --- We incorporated in Indiana on April 17, 2012, under the name Innovative Health Solutions, Inc. On March 11, 2022, we amended our Articles of Incorporation to change our name to Neuraxis, Inc. On June 23, 2022, we changed our state of incorporation from Indiana to Delaware. Our principal executive offices are located at 11550 N. Meridian Street, Suite 325, Carmel, IN 46032, and our telephone number is (812) 689-0791. Our website: www.neuraxis.com.
Neuraxis, INC annual income statement and balance sheet, FY 2022 to FY 2025, as reported in SEC filings.
| Metric | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Revenue | $2.7M | $2.5M | $2.7M | $3.6M |
| Gross profit | $2.4M | $2.2M | $2.3M | $3.0M |
| Operating income | ($3.4M) | ($6.7M) | ($7.2M) | ($7.8M) |
| Net income | ($4.8M) | ($14.6M) | ($8.2M) | ($7.8M) |
| Metric | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Total assets | $1.5M | $509K | $4.8M | $6.4M |
| Total liabilities | $7.1M | $1.9M | $2.7M | $3.0M |
| Total equity | ($5.6M) | ($1.4M) | $2.1M | $3.4M |
| Cash & equivalents | $254K | $78.6K | $3.7M | $5.0M |